Today: 27 January 2026
Subscribe
Browse Category

FDA Updates News 15 January 2026 - 23 January 2026

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

New York, Jan 23, 2026, 08:55 EST — Premarket Revelation Biosciences shares climbed roughly 2% in premarket Friday, adding to a rollercoaster week for the lightly traded biotech. Investors were reacting to the company’s newest regulatory update. The stock last changed hands near $0.85. This move is crucial as the company aims to consolidate early-stage research into one late-stage trial,…
23 January 2026
·····
Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play

Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play

New York, January 21, 2026, 11:55 AM EST — Regular session Shares of Boston Scientific Corporation held steady, edging just above $91.20 during late morning trading in New York on Wednesday. The stock is steady, with investors weighing a device-safety warning from U.S. regulators while watching Boston Scientific’s latest deal moves. Attention remains on the company’s planned Penumbra acquisition, sparking…
21 January 2026
····
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

New York, January 21, 2026, 08:47 EST — Premarket ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA. (MarketScreener) This move is significant because the FDA rejected ImmunityBio’s application last year to expand…
21 January 2026
·····
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

New York, January 20, 2026, 20:22 ET — The market has closed. Shares of ImmunityBio, listed on Nasdaq, surged Tuesday following news that U.S. regulators outlined a potential path for the company to pursue an expanded bladder cancer indication for its drug ANKTIVA. The stock closed up 17.7% at $6.48, after trading between $4.94 and $7.97 on heavy volume. (Business…
21 January 2026
·····
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

New York, Jan 20, 2026, 6:50 PM EST — After-hours Eli Lilly’s shares edged up 0.3% to close Tuesday at $1,041.29, then ticked 0.04% higher in after-hours action. The move followed news that the U.S. FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. (MarketScreener) The change is slight, but it hits home as investors keep…
21 January 2026
·····
Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares

Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares

New York, January 20, 2026, 14:21 EST — Regular session ongoing. Shares of Boston Scientific Corp climbed roughly 3.1% to $90.77 on Tuesday, clawing back some of last week’s losses. Investors digested new clinical data amid ongoing concerns over regulatory issues and deal rumors. This shift is significant since BSX is back to being a “show me” stock. Traders are…
20 January 2026
···
ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

New York, January 20, 2026, 12:42 ET — Regular session ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159…
20 January 2026
····
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss,…
18 January 2026
······
Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

New York, January 17, 2026, 15:06 (EST) — Market closed Merck & Co (MRK.N) shares dropped 1.9% on Friday, ending the day at $108.83. That’s roughly 4% shy of their 52-week peak of $112.90 hit earlier this month. (Reuters) Investors start the week focused on a new FDA fast-track program targeting quick decisions—just one to two months—on a select group…
17 January 2026
·····
Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

New York, Jan 15, 2026, 13:56 EST — Regular session Shares of Merck & Co slipped 0.2% to $110.75 on Thursday, fluctuating within a range of $108.48 to $111.06 during the day. The shift arrives as investors adjust their outlook on the U.S. Food and Drug Administration’s new fast-track review process. Initially marketed as a shortcut, the effort is already…
15 January 2026
·····
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 12:06 (EST) — Regular session Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez…
15 January 2026
····
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

NEW YORK, Jan 14, 2026, 6:33 PM EST — After-hours Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment. The FDA’s move to remove suicide warnings from GLP-1 weight-loss drugs comes at a tricky time for the sector. Demand is…
15 January 2026
····
1 2 3 … 6

Stock Market Today

  • Jardine Matheson Shares Reach 52-Week High on SGX Following New Buyback
    January 27, 2026, 3:13 AM EST. Shares of Jardine Matheson Holdings soared 2.5% to a 52-week peak of $76.64 on the Singapore Exchange after announcing a fresh buyback of 50,000 shares worth about $3.7 million. The repurchase reduces total shares outstanding, boosting investor sentiment amid a strong Singapore market performance. The rise arrives ahead of key central bank meetings: the U.S. Federal Reserve is expected to hold rates steady, while Singapore's Monetary Authority plans to announce policy updates. Jardine Matheson, a diversified conglomerate with holdings in sectors like retail and property, remains sensitive to currency and interest rate shifts. Market watchers await the Fed's Wednesday decision and MAS's policy statement Thursday for clues on future equity trends in Singapore and Jardine Matheson shares.
Go toTop